Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNASDAQ:MREONASDAQ:ZURANASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$5.51-3.5%$5.11$3.55▼$11.16$446.90M1.132.81 million shs2.41 million shsMREOMereo BioPharma Group$2.18-2.7%$2.27$1.58▼$5.02$346.62M0.531.12 million shs778,260 shsZURAZura Bio$1.00-2.0%$1.24$0.97▼$5.56$68.38M0.05409,539 shs565,550 shsZVRAZevra Therapeutics$8.45-2.3%$7.62$4.20▼$9.76$462.05M1.87642,157 shs494,565 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-3.50%-5.81%+8.68%-7.24%-24.83%MREOMereo BioPharma Group-2.68%-5.22%-12.80%-11.02%-26.10%ZURAZura Bio-1.96%-6.54%-27.01%-19.35%-81.79%ZVRAZevra Therapeutics-2.31%-1.86%+17.36%+14.34%+81.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.3928 of 5 stars3.51.00.00.02.63.30.6MREOMereo BioPharma Group2.1126 of 5 stars3.62.00.00.03.21.70.0ZURAZura Bio2.6562 of 5 stars3.62.00.00.03.22.50.6ZVRAZevra Therapeutics3.3221 of 5 stars4.62.00.00.03.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$20.20266.61% UpsideMREOMereo BioPharma Group 3.25Buy$7.71253.87% UpsideZURAZura Bio 3.13Buy$14.331,333.33% UpsideZVRAZevra Therapeutics 3.11Buy$22.29163.74% UpsideCurrent Analyst Ratings BreakdownLatest ZURA, ZVRA, MREO, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/14/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.005/9/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.004/9/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/3/2025ZURAZura BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/3/2025ZURAZura BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.003/27/2025MREOMereo BioPharma GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$7.003/26/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$20.00 ➝ $19.003/26/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K22,344.98N/AN/A$2.75 per share2.00MREOMereo BioPharma Group$1M346.62N/AN/A$0.36 per share6.06ZURAZura BioN/AN/AN/AN/A$1.85 per shareN/AZVRAZevra Therapeutics$40.59M11.38N/AN/A$1.71 per share4.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.26N/AN/AN/A-199,076.92%-55.81%-50.60%8/6/2025 (Estimated)MREOMereo BioPharma Group-$29.47M-$0.07N/AN/AN/AN/AN/AN/A8/12/2025 (Estimated)ZURAZura Bio-$69.24M-$0.70N/AN/AN/AN/A-37.36%-29.81%8/12/2025 (Estimated)ZVRAZevra Therapeutics-$46.05M-$1.90N/A42.25N/A-342.63%-159.54%-51.50%8/12/2025 (Estimated)Latest ZURA, ZVRA, MREO, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A5/13/2025Q1 2025ZVRAZevra Therapeutics-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million5/8/2025Q1 2025ZURAZura Bio-$0.17-$0.19-$0.02-$0.19N/AN/A3/26/2025Q4 2024MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.01$72.50 millionN/A3/25/2025Q4 2024ZURAZura Bio-$0.17-$0.08+$0.09-$0.08N/A$0.00 million3/11/2025Q4 2024ZVRAZevra Therapeutics-$0.39-$0.67-$0.28-$0.67$8.93 million$12.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.8716.87MREOMereo BioPharma GroupN/A6.106.10ZURAZura BioN/A10.3610.36ZVRAZevra Therapeutics0.842.882.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%MREOMereo BioPharma Group62.83%ZURAZura Bio61.14%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%MREOMereo BioPharma Group5.50%ZURAZura Bio14.23%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million68.21 millionOptionableMREOMereo BioPharma Group40159.00 million148.74 millionOptionableZURAZura Bio368.38 million50.86 millionOptionableZVRAZevra Therapeutics2054.68 million52.10 millionOptionableZURA, ZVRA, MREO, and ALT HeadlinesRecent News About These CompaniesCitizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PTMay 27 at 1:28 PM | insidermonkey.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Buy" by AnalystsMay 27 at 1:16 AM | marketbeat.comNorthern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)May 25 at 3:07 AM | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Upgraded to Buy at Wall Street ZenMay 24, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Upgraded at Wall Street ZenMay 24, 2025 | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Woodline Partners LPMay 23, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) is Velan Capital Investment Management LP's 9th Largest PositionMay 21, 2025 | marketbeat.comAll Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director NomineesMay 21, 2025 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Holdings Lowered by Stonepine Capital Management LLCMay 20, 2025 | marketbeat.comQ2 EPS Forecast for Zevra Therapeutics Raised by AnalystMay 20, 2025 | marketbeat.comResearch Analysts Offer Predictions for ZVRA Q2 EarningsMay 19, 2025 | americanbankingnews.comRoth Capital Lifts Earnings Estimates for Zevra TherapeuticsMay 18, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)May 16, 2025 | theglobeandmail.comWith 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interestMay 15, 2025 | finance.yahoo.comZevra Reports First Quarter 2025 Financial Results and Corporate UpdateMay 14, 2025 | taiwannews.com.twZevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comZevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comZevra Therapeutics, Inc. Q1 2025 Earnings PreviewMay 12, 2025 | msn.comZevra Therapeutics (ZVRA) Expected to Announce Earnings on WednesdayMay 9, 2025 | marketbeat.comZevra Therapeutics Announces Details for Q1 2025 Financial Results CallMay 6, 2025 | globenewswire.comBarclays PLC Increases Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)May 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZURA, ZVRA, MREO, and ALT Company DescriptionsAltimmune NASDAQ:ALT$5.51 -0.20 (-3.50%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$5.52 +0.02 (+0.27%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Mereo BioPharma Group NASDAQ:MREO$2.18 -0.06 (-2.68%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$2.25 +0.07 (+3.17%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Zura Bio NASDAQ:ZURA$1.00 -0.02 (-1.96%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.04 +0.04 (+4.00%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.Zevra Therapeutics NASDAQ:ZVRA$8.45 -0.20 (-2.31%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$8.41 -0.04 (-0.49%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.